Affimed N.V.
Affimed N.V.
Your view on AFMDQ
Overview
What the company does, where it operates, and who runs it.
About Affimed N.V.
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Shawn Leland
- Headquarters
- Gottlieb-Daimler-Straße 2, Mannheim, BW, DE
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Shawn Leland
- Headquarters
- Gottlieb-Daimler-Straße 2, Mannheim, BW, DE
Affimed N.V. operates as a clinical-stage biopharmaceutical firm, dedicated to the discovery and advancement of immunotherapies targeting cancer across both the United States and Germany.
Its primary therapeutic candidates include AFM13, which has successfully concluded Phase 2 trials for CD30-positive lymphoma, Phase 1b for Hodgkin lymphoma, and Phase 2b clinical evaluation for peripheral T-cell lymphoma.
Another key candidate, AFM24, a tetravalent, bispecific innate cell engager designed to bind epidermal growth factor receptor and CD16A, is currently undergoing a Phase 2a clinical trial for patients with advanced malignancies. Additionally, AFM28, another innate cell engager (ICE), is in preclinical stages for addressing acute myeloid leukemia.
Similarly, AFM32, an ICE candidate, is progressing through preclinical development for solid tumor indications. The company also maintains a collaborative partnership with Artiva Biotherapeutics, aiming to develop the combined therapy of acimtamig and AlloNK.
Furthermore, a licensing and strategic alliance with Roivant Sciences Ltd. focuses on the development and commercialization of new ICE molecules, notably AFM32, within the field of oncology.
A strategic collaboration with Genentech is also in place for advancing specific product candidates, encompassing novel NK cell engager-based immunotherapeutic agents designed to combat a range of cancers. Formerly named Affimed Therapeutics B.V., the entity adopted its current moniker, Affimed N.V., in October 2014.
Established in 2000, its corporate headquarters are situated in Mannheim, Germany.
Stock Data
Price chart, volume, and trading data.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
About this section
Valuation, profitability, liquidity and leverage ratios for Affimed N.V.. Starting points for Affimed N.V.: EPS -$7.09, beta 0.31 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
About this section
Dividend history, yield and payout sustainability for Affimed N.V.. Affimed N.V. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
About this section
Reported vs. expected earnings history for Affimed N.V.. Trailing twelve-month EPS for Affimed N.V. stands at -$7.09. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Wall Street Analyst Estimates
Analysts' price targets, ratings, and revenue and EPS estimates.
Buy
Targets, low to high
Analyst ratings
14 ratings- Strong Buy0
- Buy9
- Hold5
- Sell0
- Strong Sell0
Earnings per share estimates
| Per share | This quarterDec 2024 | Next quarterMar 2025 | This yearYear to Dec 2024 | Next yearYear to Dec 2025 |
|---|---|---|---|---|
| Average estimate | −EUR 0.80 | −EUR 0.48 | −EUR 4.06 | −EUR 1.74 |
| Lowest estimate | −EUR 0.80 | −EUR 0.48 | −EUR 4.06 | −EUR 1.74 |
| Highest estimate | −EUR 0.80 | −EUR 0.48 | −EUR 4.06 | −EUR 1.74 |
| Number of analysts | 1 | 1 | 1 | 1 |
| A year ago | −EUR 1.70 | −EUR 1.35 | −EUR 7.09 | — |
| Growth vs a year ago | +52.8% | +64.2% | +42.8% | — |
Revenue estimates
| Total | This quarterDec 2024 | Next quarterMar 2025 | This yearYear to Dec 2024 | Next yearYear to Dec 2025 |
|---|---|---|---|---|
| Average estimate | EUR 1.20M | EUR 1.30M | EUR 1.79M | EUR 8.17M |
| Lowest estimate | EUR 1.20M | EUR 1.30M | EUR 1.79M | EUR 8.17M |
| Highest estimate | EUR 1.20M | EUR 1.30M | EUR 1.79M | EUR 8.17M |
| Number of analysts | 1 | 1 | 1 | 1 |
| A year ago | EUR 1.96M | EUR 413000.00 | EUR 8.28M | — |
| Growth vs a year ago | −38.8% | +214.3% | −78.4% | — |
Financial Statements
Income statement, balance sheet, and cash flow statements.
About this section
Income statement, balance sheet and cash flow history for Affimed N.V.. Affimed N.V. has reported as a listed company since 2014. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
| Ticker | Type | Company | Sector | Exchange | Mkt cap |
|---|---|---|---|---|---|
| NTRBWNutriband Inc. | Healthcare | NASDAQ | $76.8M | ||
| NTRRNeutra Corp. | Healthcare | OTC | $291,790 | ||
| NURPFNeuren Pharmaceuticals Limited | Healthcare | OTC | $1.1B | ||
| NUVBNuvation Bio Inc. | Healthcare | NYSE | $1.3B | ||
| NUZ.AXNeurizon Therapeutics Limited | Healthcare | ASX | — | ||
| NVAXNovavax, Inc. | Healthcare | NASDAQ | $1.2B | ||
| NVCTNuvectis Pharma, Inc. | Healthcare | NASDAQ | $666.8M | ||
| NWBONorthwest Biotherapeutics, Inc. | Healthcare | OTC | $359.4M | ||
| NWPHFNewron Pharmaceuticals S.p.A. | Healthcare | OTC | $239.5M | ||
| NXTCNextCure, Inc. | Healthcare | NASDAQ | $29.5M | ||
| NYMXFNymox Pharmaceutical Corporation | Healthcare | OTC | $4.8M | ||
| NYR.AXNyrada Inc. | Healthcare | ASX | — | ||

Comments
Comments and replies from FRC members about this company.
No comments yet
Be the first to ask a question or say what you make of Affimed N.V.